DiaMedica Therapeutics (DMAC) Revenue (2018)

DiaMedica Therapeutics' (DMAC) quarterly Revenue came in at $500000.0 in Q3 2018.

DiaMedica Therapeutics (DMAC) Revenue (2018) Analysis & Trends

DiaMedica Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $500000.0 for Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 DiaMedica Therapeutics 364.72 Mn 364.72 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2018 500,000.00